Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease

SUMMIT, N.J., Feb. 18, 2025 /PRNewswire/ — An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in which humanized sickle cell mice topically treated with Vascarta’s transdermal curcumin gel formulation (“VAS-101”)…